Despite a high level of concern regarding spend on breast cancer medicines, access restrictions remain only mild to moderate. Spend in the indication is in the top three in oncology due to both medicines’ cost and high disease prevalence; however, most payers have not implemented access restrictions.

This Datamonitor Healthcare report contains a Pricing & Reimbursement module.